Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

uld provide significant scope for value creation through external growth opportunities targeting a return above cost of capital.

(6) Before the impact of inflation and any significant change to the activities of the Group, at constant exchange rates

Research and Development

During the second quarter of 2009, initiatives continued to transform the Group's Research and Development operations, with a view to continuing to refocus on innovation, gaining flexibility, and reorienting some of its existing resources to external collaborations.

On April 29, 2009, the results of the complete, in-depth review of the R&D portfolio conducted as part of the sanofi-aventis transformation program were announced. The main changes in the portfolio since that date are:

  • 4 new candidates entered Phase I:
    • SAR548304 (biliary acid reabsorption inhibitor), developed for hypercholesterolemia, and SAR153192, an anti-DLL4 monoclonal antibody developed for cancer
    • XL147 (orally-administered PI3K inhibitor) and XL765 (orally-administered double PI3K and target mTOR inhibitor), developed for cancer: sanofi-aventis has obtained an exclusive world license for both of these products, which were developed by the biotechnology company Exelixis
  • SAR 407899, a rho-kinase inhibitor, entered Phase II in erectile dysfunction.
  • BSI-201, a PARP inhibitor, developed by BiPar Sciences (recently acquired by sanofi-aventis) entered Phase III in July. This pivotal study will evaluate the product in association with chemotherapy in women with metastatic triple negative breast cancer (mTNBC), i.e. with a tumor that expresses neither the estrogen receptor nor the progesterone receptor and does not over-express the HER2 receptor.
  • Enrolment to the Phase III study, evaluating NV1FGF in critical ischemia of t
    '/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... 35 th Annual Canaccord|Genuity Growth Conference in ... Chairman and CEO, William C. Taylor , President ...
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... development of autologous cell therapies, announced today that RepliCel,s CEO, ... conference held in Minneapolis, Minnesota on ... presentation will highlight RepliCel,s 18-month milestones including CE Mark for ... , clinical data from both RCT-01 (tendon) and RCS-01 ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... (OTCQB: AHRO) ("AtheroNova"), a biotech company focused on the research ... that it has appointed Johan M. (Thijs) Spoor as a ... effective January 3, 2012. Mr. Spoor is an independent director ... the Board. "I am very pleased to ...
... Inc., has initiated its transition from technology development ... Stan Rose, Ph.D., as the company,s first chief ... Sklar, M.D., Ph.D., has agreed to join the ... pioneering the development of a novel technology with ...
... Jan. 5, 2012  ZyGEM Corp. Ltd., a developer ... of DNA and other nucleic acids, and the ... (USAMRIID), today announced the signing of a Cooperative ... of simplified sample processing solutions for biothreat agents. ...
Cached Biology Technology:AtheroNova Announces a New Board Member 2AtheroNova Announces a New Board Member 3Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 2Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 3Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 4ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... ISRAEL, August 9, 2010 Ben-Gurion University of the Negev ... Samuel and Paula Elkeles Prize for Outstanding Scientist in the ... the Shraga Segal Department of Microbiology and Immunology and vice ... of Health Sciences. He is also the Irving Sklar ...
... is available in German . , Spectroscopic techniques ... look inside materials. They exploit the interaction of light waves ... spectroscopy, researchers from Helmholtz-Zentrum Berlin fr Materialien und Energie (HZB) ... solvent so-called electron transfer. They can even make assertions ...
... of Case Western Reserve University School of Medicine, has ... Pioneer Award. One of 17 awardees to ... genetic effects, where the biological features and disease risk ... much on the genetics of ancestral generations as on ...
Cached Biology News:Ben-Gurion University of the Negev professor awarded the 2010 Elkeles Prize for Cancer Research 2Help from the dark side 2Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
... KineticScan™ Reader is Cellomics‘ latest ... for Cell-based Screening". The KineticScan ... to do both temporal and ... processes, dynamic distribution and activity ...
... Introduction of a protein into cells ... cell signaling pathways, apoptotic pathways, and transcription ... for studying the effects of a specific ... transfect the protein directly into the cell. ...
... is an innovative reagent for highly efficient ... of living cells. Unlike DNA transfection, with ... amount and timing of exogenous proteins in ... can now be studied. Real time ...
Biology Products: